Product image of Ibandronat Stada (Ibandronic Acid) supplied by GNH India

Ibandronat Stada

Active Ingredient:
Ibandronic Acid
Origin:
EU

Ibandronat Stada (Ibandronic Acid)

Ibandronic acid, the active ingredient in Ibandronat Stada, is a bisphosphonate presented as an oral tablet for oral use. It is indicated for the treatment of postmenopausal osteoporosis and for the prevention of bone loss in patients undergoing long‑term glucocorticoid therapy, helping to maintain skeletal strength and reduce fracture risk.

GNH India supplies Ibandronat Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability across regulated markets and meeting stringent regulatory requirements.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ibandronat Stada, a bisphosphonate, acts on bone remodeling to reduce resorption.
  • Postmenopausal osteoporosis: improves bone mineral density and lowers fracture risk in postmenopausal women.
  • Glucocorticoid‑induced bone loss: helps prevent loss of bone mass in patients receiving long‑term glucocorticoid therapy.

How It Works

  • Ibandronic acid binds to hydroxyapatite crystals on bone surfaces, where it is taken up by osteoclasts during bone resorption. Inside osteoclasts it inhibits farnesyl pyrophosphate synthase, a key enzyme of the mevalonate pathway, leading to loss of prenylated proteins, impaired osteoclast function, and ultimately reduced bone resorption. The drug’s high affinity for bone mineral provides a prolonged skeletal reservoir, allowing intermittent dosing while maintaining anti‑resorptive activity.

Side Effects

Ibandronat Stada may be associated with several adverse reactions, ranging from frequent mild events to rare serious conditions.

Common Side Effects

  • Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.
  • Musculoskeletal pain: transient bone, joint or muscle aches.
  • Headache: mild to moderate intensity.
  • Flu‑like symptoms: transient fever, chills or myalgia.
  • Esophageal irritation: soreness or ulceration when tablets are not taken with sufficient water.
  • Hypocalcemia: low serum calcium levels, especially in patients with vitamin D deficiency.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw: exposed necrotic bone in the maxillofacial region.
  • Atypical femoral fracture: low‑energy fracture of the subtrochanteric or diaphyseal femur.
  • Severe hypersensitivity: anaphylaxis, angioedema or severe skin reactions.

Precautions & Warnings

Before prescribing Ibandronat Stada, clinicians should consider several precautionary measures to ensure safe use.

  • Renal function: assess creatinine clearance and avoid use in severe renal impairment.
  • Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk.
  • Esophageal disorders: avoid in patients with active esophageal disease; advise upright posture after dosing.
  • Concomitant medications: review use of other bisphosphonates or drugs affecting bone metabolism.
  • Pregnancy and lactation: contraindicated; avoid use in women who are pregnant or breastfeeding.
  • Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Avoid Interactions

Ibandronat Stada can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Antacids containing aluminum or magnesium: reduce absorption; separate dosing by at least 2 hours.
  • Oral calcium supplements: interfere with tablet uptake; separate dosing by at least 2 hours.
  • NSAIDs or corticosteroids: increase risk of gastrointestinal irritation or ulceration.

Moderate Interactions (Monitor Closely)

  • Warfarin: may enhance anticoagulant effect; monitor INR.
  • Proton pump inhibitors: may affect gastric pH and absorption; observe therapeutic response.
  • Renal‑clearing drugs (e.g., aminoglycosides): combined renal stress; monitor kidney function.

Frequently Asked Questions

Ibandronat Stada is prescribed to treat postmenopausal osteoporosis and to prevent bone loss in patients who are receiving long‑term glucocorticoid therapy. By reducing bone resorption, it helps maintain skeletal strength and lowers the risk of fractures in these populations.

Ibandronic acid binds to bone mineral and is taken up by osteoclasts during bone resorption. It inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, which disrupts osteoclast function and leads to a decrease in bone breakdown, thereby preserving bone density.

The dosing regimen for Ibandronat Stada is determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Healthcare providers set the appropriate dose and frequency according to current guidelines and individual patient needs.

The safety of Ibandronat Stada during pregnancy or lactation has not been established. It is generally contraindicated in pregnant or breastfeeding women because bisphosphonates may affect fetal bone development. Women of child‑bearing potential should use effective contraception while on therapy.

To order Ibandronat Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ibandronat belongs to the bisphosphonate class like alendronate or risedronate, sharing a common mechanism of inhibiting osteoclast‑mediated bone resorption. Compared with some alternatives, ibandronate may be administered less frequently (e.g., monthly) and has a similar efficacy profile, though individual response and tolerability can vary.

Ibandronat Stada tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture, and store out of direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally as a tablet, usually on an empty stomach with a full glass of water. Patients should remain upright for at least 30 minutes after dosing and avoid eating or drinking anything other than water during that time to enhance absorption and reduce esophageal irritation.

Serious risks include osteonecrosis of the jaw, atypical femoral fractures, and severe hypersensitivity reactions such as anaphylaxis. These events are rare but require prompt medical attention if symptoms such as exposed jaw bone, unexplained thigh pain, or signs of an allergic reaction occur.

Ibandronat Stada should be avoided in patients with severe renal impairment, active esophageal disorders, known hypersensitivity to ibandronic acid, or those who are pregnant or breastfeeding. Additionally, individuals taking certain interacting medications without proper monitoring should not use the product without medical guidance.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ibandronic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT